TY - JOUR
T1 - The Association between Serum 25-Hydroxyvitamin D and Cancer Risk
T2 - Results from the Prospective KORA F4 Study
AU - Cheney, Catherine P.
AU - Thorand, Barbara
AU - Huth, Cornelia
AU - Berger, Katja
AU - Peters, Annette
AU - Seifert-Klauss, Vanadin
AU - Kiechle, Marion
AU - Strauch, Konstantin
AU - Quante, Anne S.
N1 - Publisher Copyright:
© 2018 S. Karger GmbH, Freiburg.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: Many studies have examined the relationship between vitamin D and specific types of cancer with inconsistent results. Furthermore, to date, no observational studies have demonstrated a clear relationship between vitamin D and total cancer risk. Methods: We analyzed data from a population-based prospective cohort study including 2,003 initially cancer-free participants from the KORA F4 study with baseline serum 25-hydroxyvitamin D (25(OH)D) measurements (surveyed between 2006 and 2008). We used Cox proportional hazard models to assess the association between 25(OH)D levels and incident cancer risk. Results: Within a follow-up period of 7 years, 69 of the participants developed cancer. Overall, we observed no significant relationship between serum 25(OH)D levels and cancer risk. The hazard ratio (HR) per 1 ng/ml increase in 25 (OH)D for this relationship was 1.00 (95% confidence interval (CI) 0.97-1.04) adjusting for age, sex, body mass index, and season of blood draw. This was also true in subgroup analysis for prostate cancer (HR 0.95, 95% CI 0.88-1.03), breast cancer (HR 1.03, 95% CI 0.97-1.09), and colorectal cancer (HR 0.97, 95% CI 0.88-1.07). Conclusion: Our study found no protective effect of 25(OH)D against developing cancer. However, studies with more participants and additional measurements of 25(OH)D are still needed to accurately clarify the relationship between 25(OH)D and total cancer risk.
AB - Background: Many studies have examined the relationship between vitamin D and specific types of cancer with inconsistent results. Furthermore, to date, no observational studies have demonstrated a clear relationship between vitamin D and total cancer risk. Methods: We analyzed data from a population-based prospective cohort study including 2,003 initially cancer-free participants from the KORA F4 study with baseline serum 25-hydroxyvitamin D (25(OH)D) measurements (surveyed between 2006 and 2008). We used Cox proportional hazard models to assess the association between 25(OH)D levels and incident cancer risk. Results: Within a follow-up period of 7 years, 69 of the participants developed cancer. Overall, we observed no significant relationship between serum 25(OH)D levels and cancer risk. The hazard ratio (HR) per 1 ng/ml increase in 25 (OH)D for this relationship was 1.00 (95% confidence interval (CI) 0.97-1.04) adjusting for age, sex, body mass index, and season of blood draw. This was also true in subgroup analysis for prostate cancer (HR 0.95, 95% CI 0.88-1.03), breast cancer (HR 1.03, 95% CI 0.97-1.09), and colorectal cancer (HR 0.97, 95% CI 0.88-1.07). Conclusion: Our study found no protective effect of 25(OH)D against developing cancer. However, studies with more participants and additional measurements of 25(OH)D are still needed to accurately clarify the relationship between 25(OH)D and total cancer risk.
KW - Epidemiology
KW - Prevention
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85042883922&partnerID=8YFLogxK
U2 - 10.1159/000485512
DO - 10.1159/000485512
M3 - Article
C2 - 29485414
AN - SCOPUS:85042883922
SN - 2296-5270
VL - 41
SP - 117
EP - 121
JO - Oncology Research and Treatment
JF - Oncology Research and Treatment
IS - 3
ER -